Toxic Megacolon – A Three Case Presentation
暂无分享,去创建一个
S. Rugină | L. Tuta | I. Dumitru | E. Dumitru
[1] Alexandra J. Baumann,et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection , 2017, Alimentary pharmacology & therapeutics.
[2] B. Dezsényi,et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] A. Stallmach,et al. Clostridium-difficile-Infektion , 2016, Der Internist.
[4] R. Aziz,et al. Gut microbiome alterations in patients with stage 4 hepatitis C , 2016, Gut Pathogens.
[5] L. Loo,et al. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series , 2016, BMC Infectious Diseases.
[6] M. Wilcox,et al. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission , 2016, Nature Reviews Gastroenterology &Hepatology.
[7] A. Ofosu. Clostridium difficile infection: a review of current and emerging therapies , 2016, Annals of gastroenterology.
[8] N. Khanafer,et al. Factors predictive of severe Clostridium difficile infection depend on the definition used. , 2016, Anaerobe.
[9] L. Valiquette,et al. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] B. Puri,et al. WSES guidelines for management of Clostridium difficile infection in surgical patients , 2015, World Journal of Emergency Surgery.
[11] A. Galecki,et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] L. Clough,et al. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection , 2014, Infectious Diseases and Therapy.
[13] A. Zinsmeister,et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] Linda M. Spooner,et al. Tigecycline for the Treatment of Severe Clostridium difficile Infection , 2011, The Annals of pharmacotherapy.
[15] Wei Xu,et al. Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection , 2011, Microbial Ecology.
[16] Na Young Kim,et al. [A case of pseudomembranous colitis in a juvenile rheumatoid arthritis patient taking methotrexate]. , 2010, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[17] R. Richards,et al. Toxic megacolon associated Clostridium difficile colitis. , 2010, World journal of gastrointestinal endoscopy.
[18] D. Gerding,et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.
[19] W. Witte,et al. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[20] D. Musher,et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] D. Yokoe,et al. Clinical Risk Factors for Severe Clostridium difficile–associated Disease , 2009, Emerging infectious diseases.
[22] P. Toivanen,et al. Fecal microbiota in early rheumatoid arthritis. , 2008, The Journal of rheumatology.
[23] D. Mercer,et al. Fulminant Clostridium difficile colitis , 2007, Current opinion in critical care.
[24] J. Dipersio,et al. Severity of Clostridium difficile–Associated Disease (CDAD) in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD Severity Grading System , 2007, Infection Control & Hospital Epidemiology.
[25] C. Sirio,et al. Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.
[26] L. Bodenstein,et al. SevereClostridium difficile colitis , 1995, Diseases of the colon and rectum.
[27] M. Orlandea,et al. Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients , 2016, Journal of critical care medicine.
[28] A. Naimushin,et al. [Clostridium difficile-associated diarrhea: causes and relationship to reactive arthritis]. , 2011, Harefuah.
[29] Guang-xi Li,et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .